| | Diagnosis | |
|---|
| CIN 3 | CIN 2 | CIN 1 | Other* | N/A** | P-value |
|---|
| N = 22 | N = 45 | N = 184 | N = 182 | N = 55 | Trend *** | CIN 3/2 vs CIN1/Other |
|---|
| HPV 16/18 (any) | 17 (77%) | 24 (53%) | 57 (31%) | 40 (22%) | 15 (27%) | < 0.001 | < 0.001 |
| HPV 6/11 (any) | 0 (0%) | 1 (2%) | 14 (8%) | 10 (5%) | 1 (2%) | 0.071 | 0.151 |
| 13 HR HPV types^ | 21 (95%) | 44 (98%) | 160 (87%) | 124 (68%) | 43 (78%) | 0.043 | < 0.001 |
| 9vHPV 9 types | 21 (95%) | 37 (82%) | 119 (65%) | 95 (52%) | 32 (58%) | < 0.001 | < 0.001 |
- *Other includes: metaplasia, inflammation, atrophy, atypia, and negative
- **N/A includes: insufficient and no biopsy
- ***Trend for increasing prevalence of HPV types from CIN 1- to CIN 3
- ^HPV 13 high risk types: 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68